Back

Pharmacological Studies on the Efficacy of a Polyherbal Formulation Dawa ul kurkum in DEN-Induced 2-AAF-Promoted Hepatocellular Carcinoma in Male Wistar Rats

Gupta, M.; Nimesh, H.; Sarwat, M.

2023-05-08 cancer biology
10.1101/2023.05.05.539655 bioRxiv
Show abstract

The purpose of this study was to explore the anti-cancer activity and the possible mechanism of Dawa-ul kurkum (Duk) against diethylnitrosamine (DEN)-initiated hepatocarcinogenesis in male Wistar rats. We administered Duk at 3 doses, viz., 75, 150, and 300 mg/kg/day, 2 weeks before the DEN and continued it for 16 weeks. We found that Duk significantly reduced the DEN and 2-AAF induced phenotypical changes in rats and restored the activities of serum markers. Furthermore, Duk counteracted the oxidative stress induced by carcinogens as observed by restoration in the levels of superoxide dismutase (SOD) and catalase (CAT). Duk significantly diminished the levels of malondialdehyde (MDA) in a dose dependent manner and restored the liver microarchitecture as assessed by histopathological studies. The results of immunohistochemical staining showed that Duk inhibited the DEN-induced decrease in the number of cells positive for Bid and Caspase-9. It also reduces the number of cells positive for Cyclin D. This study shows that Duk significantly protects rat liver from hepatocarcinogenesis by regulating oxidative damage and restoring serum markers. The chemopreventive effect of Duk might be through induction of apoptosis.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
PLOS ONE
● 5266 papers in training set
Top 2%
44.0%
Similar papers in this journal
2
Heliyon
○ 152 papers in training set
Top 0.5%
5.4%
Similar papers in this journal
3
Molecules
○ 39 papers in training set
Top 0.2%
4.5%
Similar papers in this journal
50% of probability mass above
4
Frontiers in Oncology
○ 103 papers in training set
Top 0.8%
4.2%
Similar papers in this journal
5
Scientific Reports
○ 3612 papers in training set
Top 23%
4.2%
Similar papers in this journal
6
Life Sciences
○ 27 papers in training set
Top 0.2%
3.3%
7
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 0.4%
2.2%
8
International Journal of Molecular Sciences
○ 494 papers in training set
Top 6%
2.2%
9
BioMed Research International
○ 28 papers in training set
Top 0.6%
2.2%
10
Molecular Biology Reports
○ 21 papers in training set
Top 0.5%
1.4%
11
PeerJ
◐ 308 papers in training set
Top 7%
1.2%
12
Biomolecules
○ 100 papers in training set
Top 2%
1.1%
13
Biochemistry and Biophysics Reports
○ 30 papers in training set
Top 1.0%
1.0%
14
Pharmaceuticals
○ 34 papers in training set
Top 1%
0.9%
15
Cancers
○ 213 papers in training set
Top 4%
0.9%
16
Frontiers in Pharmacology
○ 111 papers in training set
Top 3%
0.9%
17
Bioscience Reports
● 27 papers in training set
Top 1%
0.9%
18
Toxicology and Applied Pharmacology
○ 14 papers in training set
Top 0.3%
0.6%
19
The Journal of Pharmacology and Experimental Therapeutics
○ 18 papers in training set
Top 0.5%
0.6%
20
Diagnostics
○ 50 papers in training set
Top 2%
0.6%
21
eLife
● 5828 papers in training set
Top 69%
0.6%
22
Biochemical Pharmacology
○ 20 papers in training set
Top 0.6%
0.5%
23
Journal of Clinical Medicine
○ 97 papers in training set
Top 5%
0.5%
24
Gene Reports
○ 14 papers in training set
Top 0.8%
0.5%
25
BMC Cancer
○ 67 papers in training set
Top 2%
0.5%
26
Cells
○ 249 papers in training set
Top 9%
0.5%
27
RSC Advances
● 22 papers in training set
Top 1%
0.5%
28
Biochemical and Biophysical Research Communications
○ 84 papers in training set
Top 3%
0.5%
29
Biomedicines
○ 67 papers in training set
Top 4%
0.5%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.